Table 4 Cox proportional hazard regression models for time to recurrence (TTR), cancer-specific survival (CSS), and overall survival (OS) according to blood platelet count and clinicopathological characteristics
From: Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer
TTRa | CSSb | OSc | |||||||
|---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | |
Patient age (< 65 vs. ≥ 65) | 1.25 | 0.72–2.17 | 0.428 | 1.90 | 1.12–3.24 | 0.018 | 1.93 | 1.24–3.00 | 0.003 |
Patient gender (male vs. female) | 0.93 | 0.56–1.55 | 0.794 | 1.45 | 0.90–2.32 | 0.124 | 1.10 | 0.76–1.61 | 0.605 |
Tumor invasion (T1–T2 vs. T3–T4) | 1.86 | 0.91–3.80 | 0.091 | 1.25 | 0.65–2.39 | 0.504 | 1.20 | 0.74–1.96 | 0.456 |
Nodal metastases (N0 vs. N1–N2) | 4.89 | 2.50–9.57 | < 0.001 | 2.66 | 1.40–5.05 | 0.003 | 2.10 | 1.29–3.39 | 0.003 |
Distant metastases (M0 vs. M1) | – | – | – | 6.43 | 3.63–11.4 | < 0.001 | 4.61 | 2.80–7.62 | < 0.001 |
Tumor location (colon vs. rectum) | 1.13 | 0.61–2.09 | 0.697 | 0.86 | 0.51–1.46 | 0.577 | 0.83 | 0.53–1.31 | 0.430 |
Preoperative radiotherapy or chemoradiotherapy (no vs. yes) | 1.25 | 0.61–2.53 | 0.541 | 1.43 | 0.69–2.94 | 0.334 | 1.36 | 0.75–2.46 | 0.319 |
Lymphatic invasion (no vs. yes) | 1.20 | 0.64–2.24 | 0.572 | 1.89 | 1.01–3.54 | 0.046 | 1.33 | 0.83–2.14 | 0.236 |
mGPS (0 vs. 1–2) | 0.69 | 0.29–1.65 | 0.402 | 1.72 | 1.00–2.96 | 0.049 | 1.67 | 1.07–2.61 | 0.023 |
Normocytic anemia (no vs. yes) | 0.89 | 0.47–1.67 | 0.709 | 1.34 | 0.82–2.20 | 0.246 | 1.49 | 1.00–2.22 | 0.052 |
Blood platelet count (< 400 × 109/L vs. ≥ 400 × 109/L) | 0.77 | 0.30–1.99 | 0.594 | 0.76 | 0.39–1.48 | 0.418 | 0.68 | 0.38–1.22 | 0.197 |
Aspirin (no vs. yes) | 1.22 | 0.68–2.19 | 0.499 | 0.94 | 0.52–1.68 | 0.833 | 1.13 | 0.73–1.75 | 0.590 |